IAS News and Literature Updates:
March 2017
 From the President's Desk:
Yuji Matsuzawa

Exciting results of the effects of inhibiting PCSK9 on the risk of having a cardiovascular event were presented at the recent meeting of the American College of Cardiology (ACC) held in March 2017 in Washington, DC.

The FOURIER trial was the first trial to investigate the cardiovascular benefits and safety of evolocumab, a monoclonal antibody that inhibits the action of PCSK9 in plasma in an effect that increases the number of cell surface LDL receptors and thus lowers the level of LDL cholesterol in plasma. The study was conducted in more than 27,000 people who remained at high risk despite taking effective doses of statins.
> Complete Article <

Faculty and Participants of the OSLA course on Lipid Metabolism and Cardiovascular Risk, Muscat
February 25-27, 2017
The International Atherosclerosis Society (IAS) and the Oman Society of Lipid and Atherosclerosis (OSLA) just concluded the 3rd IAS – OSLA course on Lipid Metabolism and Cardiovascular Risk which was held in Muscat, Oman (February 25-27, 2017) and co-chaired by Profs. Yuji Matsuzawa and Philip Barter of the International Atherosclerosis Society and Dr. Khalid Al-Rasadi, President of the Oman Society of Lipid and Atherosclerosis.
The 4th IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk will be held February, 2018
> Complete Report <
> Scientific Program <
Slide Library of the Course will be posted at: http://www.athero.org/slidelibrary.asp

Risk factors for atherosclerotic cardiovascular disease (ASCVD) are variable among patients with Familial Hypercholesterolaemia (FH). SAFEHEART is a multicentre, nationwide, long-term prospective contemporary cohort study of a molecularly defined FH population with or without previous ASCVD. A robust risk prediction equation (SAFEHEART-RE) has been developed using this unique cohort that shows that the risk of incident ASCVD may be estimated in FH patients using clinical and laboratory parameters including age, gender, history of ASCVD, blood pressure, body mass index, smoking, and plasma LDL-C and lipoprotein (a) levels. The Harrell's C index for this model was 0.85.
This information will allow more accurate ASCVD risk prediction in FH and will potentially increase the efficiency of care and use of newer lipid lowering therapies. The SAFEHEART-RE is an accurate tool to implement these predictors in daily clinical practice. You can view at https://www.ncbi.nlm.nih.gov/pubmed/28275165.

Faculty and Participants of the Lipid Masters Class organized by Lipid LAI Habitat Centre, Delhi
Aug. 3-5, 2016
A Lipid Master Class with accreditation from IAS was organised by Lipid LAI between Aug 3-5 2016 at the Habitat Centre, Delhi and was a great success. The overall aim of the Lipid Master class is was to provide Health care professionals with an educational programme that will enhance their knowledge and understanding of the management of Lipids and ultimately improve patient care. Master class been was designed to incorporate relevant and practical topics related to the management of Lipids. The course aimed to combine both presentation and interactive case based learning.
Complete Report <
Also included in this Newsletter:

Toronto, Canada
June 9 - 12, 2018

XVIII International Symposium on Atherosclerosis

In the News: 

Liver Fat Accumulation and Accelerated Atherosclerosis: Is PCSK9 a Missing Link?

By: Luca Valenti, Paola Dongiovanni, and Massimiliano Ruscica

Nonalcoholic fatty liver disease (NAFLD), which is hepatic fat accumulation exceeding 5% of liver weight in the absence of at risk alcohol intake, represents nowadays the leading cause of liver damage worldwide. NAFLD is considered the hepatic manifestation of insulin resistance - its main clinical risk factors being obesity, type 2 diabetes, and atherogenic dyslipidemia.

View Complete Commentary <

Autoimmunity, Oxidative Stress, Lipoprotein Dysfunction, and Cardiovascular Disease: Is There a Role for Autoantibodies?
By: J. Rodríguez-Carrio

Systemic autoimmune conditions such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) are associated with greater rates of cardiovascular disease (CVD) morbidity than the general population. This greater risk cannot be solely attributed to traditional CV risk factors, and different non-traditional factors such as chronic inflammation, immune dysregulation, or exposure to treatments seem to be involved.

> View Complete Commentary <


April 8, 2017

Chilean Working Group on Atherosclerosis Course: Advances in the Treatment of Hypertension and Dyslipidemia
Temuco, Chile

Email: rodrigoalonsok@gmail.com

May 13, 2017

Chilean Working Group on Atherosclerosis Course: Advances in the Treatment of Hypertension and Dyslipidemia
Concepcion, Chile

Email: rodrigoalonsok@gmail.com

May 15-17, 2017

6th ICCR Congress on Chronic Societal Cardiometabolic Disease
Quebec City, QC, Canada

View Meeting Website

May 20, 2017

Educational Seminar on Familial Hypercholesterolemia
Kuala Lampur City, Malaysia

View Meeting Website

May 27, 2017

Chilean Working Group on Atherosclerosis Course: Advances in the Treatment of Hypertension and Dyslipidemia
Viña, Chile

Email: rodrigoalonsok@gmail.com

For a complete listing of all Member Society meetings and educational activities

Please Click Here


The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission: Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, Ono Pharmaceutical Co., Ltd., OSLA - Oman Society of Lipids and Atherosclerosis, Otsuka Pharmaceutical Co., Ltd., Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College.

>> Back To Top <<
IAS Newsletter Editors
Website Editorial Board
Scott M. Grundy, MD, PhD
Dallas, TX, USA

Associate Editors
Stefano Bellosta, PhD
Milan, Italy
Emanuela Folco, PhD
Milan, Italy
Ann Jackson, MBA
Houston, TX, USA

Website & Newsletter Editors
Elena Colombo
Milan, Italy
Yelonda Williams, BA
Dallas, TX, USA


You are a valued member of the International Atherosclerosis Society. You are receiving this email because you opted in at our website - www.athero.org

Unsubscribe <<Email Address>> from this list.

Our mailing address is:
International Atherosclerosis Society
Fondazione Giovanni Lorenzini Medical Science Foundation
viale Piave 35
Milan, Italy 20129

Add us to your address book

Copyright (C) 2017 International Atherosclerosis Society All rights reserved.

Forward this email to a friend
Update your profile